Publications by authors named "McBride Ali"

Claim this Profile
F
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.
Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, Stuart L Goldberg, Mauricette Michallet, Ali McBride

Leuk Lymphoma· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study.
Leslie A Andritsos, Ali McBride, Derek Tang, Victoria Barghout, Enrico Zanardo

Leuk Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents.
Guillermo Garcia-Manero, Rayna K Matsuno, Ali McBride, Hina Mohammed, Danny Idryo

Clin Lymphoma Myeloma Leuk· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
John Mascarenhas, Claire Harrison, Tammy A Schuler, Djibril Liassou, Marné Garretson, Ali McBride

Clin Lymphoma Myeloma Leuk· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
Andrew J Klink, Ajeet Gajra, Russell L Knoth, Landon Marshall, Ying Hou, Ali McBride

Leuk Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis.
Sudipto Mukherjee, Cherrishe Brown-Bickerstaff, Angelica Falkenstein, Adeola Y Makinde, Emily Bland, Ali McBride

Hemasphere· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.
Nada Alsuhebany, Congshan Pan, Eileen Holovac, Brian Do, Ali McBride

Blood Lymphat Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The implementation of value-based frameworks, clinical care pathways, and alternative payment models for cancer care in the United States.
Rupesh Panchal, Madeline Brendle, Sabrina Ilham, Aditi Kharat, Howard W Schmutz, Ali McBride

J Manag Care Spec Pharm· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
Andrew M Brunner, David Huggar, Ronda Copher, Zheng-Yi Zhou, Miriam L Zichlin, Ali McBride

Leuk Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
Ali McBride, John Brokars, Sheila Reiss Reddy, Eunice Chang, Marian H Tarbox

Acta Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacist biosimilar survey reveals knowledge gaps.
James G Stevenson, Dorothy McCabe, Melissa McGrath, Ali McBride

J Am Pharm Assoc (2003)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study.
John Mascarenhas, Hiep Nguyen, Ashley Saunders, Louisa Oliver, Hannah Tomkinson, Ali McBride

Future Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention.
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter

Expert Rev Pharmacoecon Outcomes Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment.
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter

Expert Rev Pharmacoecon Outcomes Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic value of knowing BRCA status: testing for optimizing treatment in recurrent epithelial ovarian cancer.
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter

Expert Rev Pharmacoecon Outcomes Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm.
Catherine M Lockhart, Cara L McDermott, Aaron B Mendelsohn, James Marshall, Ali McBride

J Med Econ· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia.
Ashley Tabah, David Huggar, Si-Tien Wang, Scott J Johnson, Ronda M Copher, Ali McBride

Future Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
Andrew J Klink, Ajeet Gajra, Russell L Knoth, Landon Marshall, Ying Hou, Ali McBride

Leuk Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type.
Neda Alrawashdh, Ali McBride, Mok Oh, Nimer Alkhatib, Christopher Lee

J Adv Pract Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia.
Neda Alrawashdh, Ali McBride, Brian Erstad, Joann Sweasy, Daniel O Persky

Value Health· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.
David Huggar, Russell L Knoth, Ronda Copher, Zhun Cao, Craig Lipkin, Ali McBride

Future Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey.
Ali McBride, Sarah Hudson-DiSalle, Jeff Pilz, Mark Hamm, Brooke Boring

JCO Oncol Pract· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer.
Neda Alrawashdh, Jamie Vraney, Briana M Choi, Abdulaali R Almutairi, Ivo Abraham, Ali McBride

Future Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling.
Nada Alsuhebany, Jamie Brown, Jacquelyne Echave, Ali McBride

J Adv Pract Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.
Kelley D Mayden, John M Kelton, Joanne C Ryan, Ali McBride

J Adv Pract Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis